Daix (France), January 6, 2021 - Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS) and other diseases with significant unmet medical need, today announced that Frédéric Cren, Chairman, CEO and cofounder of Inventiva, has been invited to present a corporate overview, followed by a Q&A session, and engage in 1×1 investor meetings at the upcoming 39th Annual J.P. Morgan Annual Healthcare Conference, being held virtually on January 11-14, 2021.
Download PDF

Attachments

  • Original document
  • Permalink

Disclaimer

Inventiva SA published this content on 06 January 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 06 January 2021 21:03:00 UTC